PF-Atlasניסויים קליניים › NCT02478268

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

Hyperpolarized 129-Xenon gas · שלב 1

מזהה רישום
NCT02478268
שלב
שלב 1
סטטוס
הושלם
תרופה / התערבות
Hyperpolarized 129-Xenon gas
ממן
Bastiaan Driehuys
התחלה
2015-05
מספר משתתפים
64
מיקומים
2

על הניסוי

The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in patients receiving treatment as well as those who don't. 129Xe is a special type of xenon gas and when inhaled during MRI may be able to show areas of abnormal thickening of parts of the lungs. These images combined with images taken with injected contrast agents or other types of MRI may provide a better way to look at lung structure and function in patients with IPF. The ultimate goal is to predict how a particular patient might respond to a particular therapy and to observe such responses earlier than conventional tests. The investigators anticipate that the images acquired in this study will provide more specific information about lung disease than standard lung function tests. The use of 129Xe MRI is investigational. "Investigational" means that these tests have not yet been approved by the US Food and Drug Administration and are being tested in research studies like this one. In addition, standard MRI with contrast is not typically done as standard of care for monitoring progression of IPF, therefore, its use in this study is also considered investigational. Healthy volunteers are being asked to participate in this study because the investigators need to develop a database of functional images that are representative of healthy lungs.

צפו ב-NCT02478268 ב-ClinicalTrials.gov ←

קישורים קשורים

הבהרה רפואית. דף זה מסכם נתוני ניסוי ציבוריים עבור NCT02478268 למידע בלבד. אין זה ייעוץ רפואי, המלצה או הצעה להשתתף. אמתו פרטים ב-ClinicalTrials.gov ומול רופא מוסמך.